英国急性髂股深静脉血栓早期血管内血栓清除的成本效益
本研究从英国医疗付费方视角,用决策树与马尔可夫模型比较导管导向溶栓、药物化学血栓清除与单纯口服抗凝治疗急性髂股深静脉血栓的成本效益,结果示导管导向溶栓和药物化学血栓清除均较口服抗凝成本更低且质量调整生命年更高,但概率敏感性分析提示参数不确定性较大。
要点
- 导管导向溶栓较口服抗凝终身成本低5163英镑且多0.6个质量调整生命年,为优势方案。
- 药物化学血栓清除较口服抗凝终身成本低917英镑且多0.3个质量调整生命年,为优势方案。
- 概率敏感性分析提示参数不确定性较大,需未来临床与流行病学研究进一步明确。
核心结论
- 在英国,急性髂股深静脉血栓的早期介入治疗具有成本效益。
- 未来需临床与流行病学研究来刻画参数不确定性。
- 有必要对现代实践、替代治疗和优化照护模式开展进一步分析。
研究设计与样本
- 研究采用决策树(急性深静脉血栓并发症)与马尔可夫模型(长期并发症如血栓后综合征)联合的决策分析模型,包含无血栓后综合征、轻度、中度、重度血栓后综合征和死亡五个状态。
- 所有患者以急性深静脉血栓起始,存活急性并发症者进入马尔可夫模型,循环周期为六个月。
- 分析采用医疗付费方视角和终身时间跨度,并按血栓病史导致的超额死亡进行调整。
- 概率、转移概率、死亡率和效用值数据来自已发表文献,成本数据来自英国国家医疗服务体系收费标准和已发表文献。
主要发现
- 终身来看,口服抗凝治疗成本为37206英镑,高于导管导向溶栓的32043英镑和药物化学血栓清除的36288英镑。
- 口服抗凝治疗的平均终身质量调整生命年为12.9,低于导管导向溶栓的13.5和药物化学血栓清除的13.3。
- 增量成本效益分析中,导管导向溶栓较口服抗凝成本低5163英镑且多0.6个质量调整生命年,药物化学血栓清除较口服抗凝成本低917英镑且多0.3个质量调整生命年,两者均为优势方案。
- 单因素敏感性分析结果稳健,但概率敏感性分析提示参数不确定性较大。
关键数值与推荐
- 口服抗凝治疗终身成本37206英镑、平均终身质量调整生命年12.9。
- 导管导向溶栓终身成本32043英镑、平均终身质量调整生命年13.5。
- 药物化学血栓清除终身成本36288英镑、平均终身质量调整生命年13.3。
- 导管导向溶栓较口服抗凝的增量成本为-5163英镑、增量质量调整生命年为+0.6。
- 药物化学血栓清除较口服抗凝的增量成本为-917英镑、增量质量调整生命年为+0.3。
临床怎么用
- 原文结论为英国急性髂股深静脉血栓早期介入治疗具有成本效益,未据此给出具体推荐。
局限性
- 概率敏感性分析提示参数不确定性较大。
- 未来需临床与流行病学研究来刻画参数不确定性。
- 有必要对现代实践、替代治疗和优化照护模式开展进一步分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Early clot removal using endovascular intervention aims to reduce post-thrombotic syndrome (PTS) following iliofemoral deep venous thrombosis (DVT). This may reduce long term morbidity but incurs a higher initial cost. This study examined the cost effectiveness of catheter directed thrombolysis (CDT) and pharmacochemical thrombectomy (PMT) compared with oral anticoagulation (OAC) alone for treatment of acute iliofemoral DVT in the United Kingdom. METHODS: A combined decision tree (acute DVT complications) and Markov model (long term complications [PTS]) was used for decision analytic modelling with five states: no PTS, mild PTS, moderate PTS, severe PTS, and dead. All patients started with acute DVT. Patients who survived acute complications transitioned into the Markov model. Cycle time was six months. A healthcare payer perspective and lifetime horizon was used, adjusting for excess mortality due to history of thrombosis. Data for probabilities, transition probabilities, mortality, and utilities were obtained from the published literature. Cost data were obtained from UK NHS tariffs and published literature. Outcomes were mean lifetime cost, quality adjusted life years (QALYs), and cost effectiveness. RESULTS: Over a patient's lifetime, OAC was more costly (£37 206) than CDT (£32 043) and PMT (£36 288). Mean lifetime QALYs for OAC (12.9) were lower than CDT (13.5) and PMT (13.3). Therefore, in the incremental cost effectiveness analysis, both CDT and PMT were dominant: CDT was less costly (-£5 163) and more effective (+0.6 QALYs) than OAC, and PMT was also less costly (-£917) and more effective (+0.3 QALYs) than OAC. Results were robust to univariable sensitivity analyses, but probabilistic sensitivity analyses suggested considerable parameter uncertainty. CONCLUSION: Early interventional treatment of iliofemoral DVT is cost effective in the UK. Future clinical and epidemiological studies are needed to characterise parameter uncertainty. Further analysis of modern practice, alternative treatments, and optimised care models is warranted.
引用
- Babigumira JB, Black SA, Lubinga SJ, et al. Cost Effectiveness of Early Endovenous Thrombus Removal for Acute Iliofemoral Deep Vein Thrombosis in the United Kingdom. Eur J Vasc Endovasc Surg. 2023. PMID: 37633444. doi:10.1016/j.ejvs.2023.08.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。